Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma

  • E. Huland
  • H. Huland
  • H. Heinzer


Continuous high-dose local administration of natural interleukin-2 (nIL-2) is tolerated without side effects in advanced-cancer patients and induces complete remission and local and systemic immunoactivation, as we have shown previously [8]. Those facts support our belief that interleukins should be administered locally, rather than systemically, for effective treatment of carcinoma. Local administration can be expected to induce fewer side effects and to activate tumor-infiltrating immune cells, which are reported to be 100 times more cytotoxic than activated blood cells [11]. The local use of interleukins is also more economical in that it reduces renal loss of small molecules. Although metastatic tumor disease seems not to be suitable for a local approach, the addition of local immunoactivation to systemic treatment might improve the therapeutic effectiveness without increasing toxicity.


Renal Cell Carcinoma Bone Metastasis Pulmonary Metastasis Metastatic Renal Cell Carcinoma ECOG Performance Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Atzpodien J, Körfer A, Franks CR, et al. (1990) Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet 335: 1509PubMedCrossRefGoogle Scholar
  2. 2.
    Bergmann L, Weidmann E, Mitrou PS, et al. (1990) Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie 13: 137Google Scholar
  3. 3.
    Daniele RP (ed) (1988) Immunology and immunologic diseases of the lung. Blackwell Scientific Publ, OxfordGoogle Scholar
  4. 4.
    Dye ES (1986) The antimetastatic function of concomitant antitumor immunity. J Immunol 136: 1510PubMedGoogle Scholar
  5. 5.
    Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310PubMedGoogle Scholar
  6. 6.
    Gorrelick E (1983) Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 39: 71CrossRefGoogle Scholar
  7. 7.
    Heinzer H, Huland E, Huland H (1990) Activated eosinophil leukocytes in interleukin-2 (IL-2) treated patients: Evidence for a new antitumor effector mechanism. J Cancer Res Clin Oncol 116 (Suppl I): 369Google Scholar
  8. 8.
    Huland E, Huland H (1989) Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469PubMedGoogle Scholar
  9. 9.
    Lee KH, Talpaz M, Rothberg JM, et al. (1989) Concomitant administration of recombinant human interleukin-2 and recombinant interferona2A in cancer patients: a phase I study. J Clin Oncol 7: 1726PubMedGoogle Scholar
  10. 10.
    Negrier S, Philip T, Stoter G, et al. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 25: 21Google Scholar
  11. 11.
    Rosenberg SA, Speiss P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 880Google Scholar
  13. 13.
    Rosenberg SA, Lotze MT, Yang JC, et al. (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863PubMedGoogle Scholar
  14. 14.
    West WH, Tauer KW, Yannelli JR, et al. (1987) Constant infusion-recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • E. Huland
    • 1
  • H. Huland
    • 1
  • H. Heinzer
    • 1
  1. 1.Urologische KlinikKlinikum Steglitz der Freien UniversitätBerlin 45Germany

Personalised recommendations